Sanyal, Arun J.
Virginia Commonwealth University
104 papers on CoChatORCID 0000-0001-8682-5748
Most cited papers
- Verified
Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: The randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trial
Mingrone, G., van Baar, A. C., Devière, J., Hopkins, D., Moura, E., Cercato, C., Rajagopalan, H., Lopez-Talavera, J. C., White, K., Bhambhani, V., et al. (2022) · Gut
Diabetes Treatment and ManagementBariatric Surgery and Outcomes
Cited by 120
- Verified
Digital pathology with artificial intelligence analyses provides greater insights into treatment-induced fibrosis regression in NASH
Naoumov, N. V., Brees, D., Loeffler, J., Chng, E., Ren, Y., Lopez, P., Tai, D., Lamle, S., & Sanyal, A. J. (2022) · Journal of Hepatology
Liver Disease Diagnosis and TreatmentLiver physiology and pathology
Cited by 115
- Verified
Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis
Loomba, R., Huang, D. Q., Sanyal, A. J., Anstee, Q. M., Trauner, M., Lawitz, E. J., Ding, D., Ma, L., Jia, C., Billin, A., et al. (2023) · Gut
Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity
Cited by 110
- Verified
Adverse muscle composition predicts all‐cause mortality in the UK Biobank imaging study
Linge, J., Petersson, M., Forsgren, M. F., Sanyal, A. J., & Dahlqvist Leinhard, O. (2021) · Journal of Cachexia, Sarcopenia and Muscle
Nutrition and Health in AgingBody Composition Measurement Techniques
Cited by 108
- Verified
Hepatic and renal improvements with FXR agonist vonafexor in individuals with suspected fibrotic NASH
Ratziu, V., Harrison, S. A., Loustaud-Ratti, V., Bureau, C., Lawitz, E., Abdelmalek, M., Alkhouri, N., Francque, S., Girma, H., Darteil, R., et al. (2023) · Journal of Hepatology
Liver Disease Diagnosis and TreatmentLiver physiology and pathology
Cited by 101
- Verified
Lipotoxicity in NASH
Fuchs, M., & Sanyal, A. J. (2012) · Journal of Hepatology
Liver Disease Diagnosis and TreatmentLiver physiology and pathology
Cited by 97
- Verified
A Phase 2 Double Blinded, Randomized Controlled Trial of Saroglitazar in Patients With Nonalcoholic Steatohepatitis
Siddiqui, M. S., Idowu, M. O., Parmar, D., Borg, B. B., Denham, D., Loo, N. M., Lazas, D., Younes, Z., & Sanyal, A. J. (2021) · Clinical Gastroenterology and Hepatology
Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity
Cited by 96
- Verified
Is Fatty Liver Associated With Depression? A Meta-Analysis and Systematic Review on the Prevalence, Risk Factors, and Outcomes of Depression and Non-alcoholic Fatty Liver Disease
Xiao, J., Lim, L. K. E., Ng, C. H., Tan, D. J. H., Lim, W. H., Ho, C. S. H., Tan, E. X. X., Sanyal, A. J., & Muthiah, M. D. (2021) · Frontiers in Medicine
Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health Effects
Cited by 94
- Verified
Recent advances in nonalcholic fatty liver disease
Greenfield, V., Cheung, O., & Sanyal, A. J. (2008) · Current Opinion in Gastroenterology
Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health Effects
Cited by 94
- Verified
Increases and decreases in liver stiffness measurement are independently associated with the risk of liver-related events in NAFLD
Gawrieh, S., Vilar-Gomez, E., Wilson, L. A., Pike, F., Kleiner, D. E., Neuschwander-Tetri, B. A., Diehl, A. M., Dasarathy, S., Kowdley, K. V., Hameed, B., et al. (2024) · Journal of Hepatology
Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity
Cited by 94
- Verified
Enhancement of functional connectivity, working memory and inhibitory control on multi-modal brain MR imaging with rifaximin in cirrhosis: implications for the gut-liver-brain axis
Ahluwalia, V., Wade, J. B., Heuman, D. M., Hammeke, T. A., Sanyal, A. J., Sterling, R. K., Stravitz, R. T., Luketic, V., Siddiqui, M. S., Puri, P., et al. (2014) · Metabolic Brain Disease
Liver Disease and TransplantationAdvanced MRI Techniques and Applications
Cited by 92
- Verified
The Commensal Microbe V eillonella as a Marker for Response to an FGF19 Analog in NASH
Loomba, R., Ling, L., Dinh, D. M., DePaoli, A. M., Lieu, H. D., Harrison, S. A., & Sanyal, A. J. (2021) · Hepatology
Gut microbiota and healthLiver Disease Diagnosis and Treatment
Cited by 88
- Verified
SOMAscan Proteomics Identifies Serum Biomarkers Associated With Liver Fibrosis in Patients With NASH
Luo, Y., Wadhawan, S., Greenfield, A., Decato, B. E., Oseini, A. M., Collen, R., Shevell, D. E., Thompson, J., Jarai, G., Charles, E. D., et al. (2021) · Hepatology Communications
Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity
Cited by 87
- Verified
PROMIS computerised adaptive tests are dynamic instruments to measure health-related quality of life in patients with cirrhosis: PROMIS tools for quality of life assessment in cirrhosis
Bajaj, J. S., Thacker, L. R., Wade, J. B., Sanyal, A. J., Heuman, D. M., Sterling, R. K., Gibson, D. P., Stravitz, R. T., Puri, P., Fuchs, M., et al. (2011) · Alimentary Pharmacology & Therapeutics
Psychometric Methodologies and TestingLiver Disease and Transplantation
Cited by 83
- Verified
Clinical Aspects of Fatty Liver Disease
Choudhury, J., & Sanyal, A. J. (2004) · Seminars in Liver Disease
Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health Effects
Cited by 82
- Verified
An Evaluation of the Collagen Fragments Related to Fibrogenesis and Fibrolysis in Nonalcoholic Steatohepatitis
Luo, Y., Oseini, A., Gagnon, R., Charles, E. D., Sidik, K., Vincent, R., Collen, R., Idowu, M., Contos, M. J., Mirshahi, F., et al. (2018) · Scientific Reports
Liver Disease Diagnosis and TreatmentLiver physiology and pathology
Cited by 74
- Verified
Placebo effect on progression and regression in NASH: Evidence from a meta‐analysis
Ng, C. H., Xiao, J., Lim, W. H., Chin, Y. H., Yong, J. N., Tan, D. J. H., Tay, P., Syn, N., Foo, R., Chan, M., et al. (2022) · Hepatology
Liver Disease Diagnosis and TreatmentLiver Diseases and Immunity
Cited by 69
- Verified
The Transcriptomic Signature Of Disease Development And Progression Of Nonalcoholic Fatty Liver Disease
Cazanave, S., Podtelezhnikov, A., Jensen, K., Seneshaw, M., Kumar, D. P., Min, H.-K., Santhekadur, P. K., Banini, B., Mauro, A. G., M. Oseini, A., et al. (2017) · Scientific Reports
Liver Disease Diagnosis and TreatmentLiver physiology and pathology
Cited by 66
- Verified
Non-Invasive Biomarkers of Nonalcoholic Steatohepatitis: the FNIH NIMBLE project
Sanyal, A. J., Shankar, S. S., Calle, R. A., Samir, A. E., Sirlin, C. B., Sherlock, S. P., Loomba, R., Fowler, K. J., Dehn, C. A., Heymann, H., et al. (2022) · Nature Medicine
Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health Effects
Cited by 56
- Verified
Hepatic, extra-hepatic outcomes and causes of mortality in NAFLD - an umbrella overview of systematic review of meta-analysis
Xiao, J., Ng, C. H., Chan, K. E., Fu, C., Tay, P., Yong, J. N., Lim, W. H., Tan, D. J. H., Syn, N., Wong, Z. Y., et al. (2023) · Journal of Clinical and Experimental Hepatology
Liver Disease Diagnosis and TreatmentAlcohol Consumption and Health Effects
Cited by 56
- Verified
Endoscopic duodenal mucosal resurfacing improves glycaemic and hepatic indices in type 2 diabetes: 6-month multicentre results
van Baar, A. C. G., Beuers, U., Wong, K., Haidry, R., Costamagna, G., Hafedi, A., Deviere, J., Ghosh, S. S., Lopez-Talavera, J. C., Rodriguez, L., et al. (2019) · JHEP Reports
Bariatric Surgery and OutcomesDiabetes Treatment and Management
Cited by 55
- Verified
AI-based automation of enrollment criteria and endpoint assessment in clinical trials in liver diseases
Iyer, J. S., Juyal, D., Le, Q., Shanis, Z., Pokkalla, H., Pouryahya, M., Pedawi, A., Stanford-Moore, S. A., Biddle-Snead, C., Carrasco-Zevallos, O., et al. (2024) · Nature Medicine
Liver Disease Diagnosis and TreatmentArtificial Intelligence in Healthcare and Education
Cited by 54
- Verified
Metabolic syndrome and its association with nonalcoholic steatohepatitis
Bril, F., Sanyal, A., & Cusi, K. (2023) · Clinics in Liver Disease
Liver Disease Diagnosis and TreatmentDiabetes, Cardiovascular Risks, and Lipoproteins
Cited by 52
- Verified
Activation of the GP130-STAT3 axis and its potential implications in nonalcoholic fatty liver disease
Min, H.-K., Mirshahi, F., Verdianelli, A., Pacana, T., Patel, V., Park, C.-G., Choi, A., Lee, J.-H., Park, C.-B., Ren, S., et al. (2015) · American Journal of Physiology-Gastrointestinal and Liver Physiology
Liver Disease Diagnosis and TreatmentCytokine Signaling Pathways and Interactions
Cited by 45
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free